Business Wire

NJ-ALPHAWAVE-SEMI

30.1.2024 17:31:33 CET | Business Wire | Press release

Share
Nubis Communications and Alphawave Semi Showcase First Demonstration of Optical PCI Express 6.0 Technology

Nubis Communications, Inc., provider of low-latency high-density optical inter-connect (HDI/O), and Alphawave Semi (LN: AWE), a global leader in high-speed connectivity and compute silicon for the world’s technology infrastructure, today announced their upcoming demonstration of PCI Express 6.0 technology driving over an optical link at 64GT/s per lane. Data Center providers are exploring the use of PCIe over Optics to greatly expand the reach and flexibility of the interconnect for memory, CPUs, GPUs, and custom silicon accelerators to enable more scalable and energy-efficient clusters for Artificial Intelligence and Machine Learning (ML/AI) architectures.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130752202/en/

Nubis Communications and Alphawave Semi will be showing a live demonstration in the Tektronix booth at DesignCon, the leading conference for advanced chip, board, and system design technologies. An Alphawave Semi PCIe Subsystem with PiCORE Controller IP and PipeCORE PHY will directly drive and receive PCIe 6.0 traffic through a Nubis XT1600 linear optical engine to demonstrate a PCIe 6.0 optical link at 64GT/s per fiber, with optical output waveform measured on a Tektronix sampling scope with a high-speed optical probe.

Optical transmission technology can be leveraged to greatly extend link distances at the same bandwidths compared with copper cables, supporting the larger cluster sizes needed to support ever-larger AI/ML servers distributed over multiple nodes, and enabling innovation in new disaggregated network architectures. The Nubis XT1600 optical engine supports up to 16 lanes of high-density PCIe Gen 6.0 or 100 Gbps/lane Ethernet optical connectivity without incorporating retimers.

“Our high level of integration with 16 lanes full-duplex in a single low-power, low-latency optical engine is a great match to the maximum bandwidth of PCIe x16 for next-generation compute and storage deployments,” said Scott Schube, VP of Marketing at Nubis Communications. “Our demonstration of the Nubis XT1600 linear optical engine and Alphawave Semi’s PCIe 6.0 Controller and PHY IP showcases the viability of a PCIe® 6.0 x8 link over optical fiber at 64 GT/s.”

“AI applications are reshaping data center networks, with hyperscalers deploying increasingly large clusters of disaggregated servers distributed over longer distances. This shift has generated heightened interest in PCIe over Optics among several of our customers,” said Tony Chan Carusone, CTO at Alphawave Semi. “Through our collaboration with Nubis, we’re pleased to demonstrate how we’re leveraging Alphawave Semi’s leadership in connectivity IP and silicon to enable PCIe optical connectivity solutions that accelerate high-performance AI computing and data infrastructure.”

Availability

The Nubis XT1600™ linear optical engine is available now for sampling, please contact via nubis-inc.com.

More on Alphawave Semi’s PCIe Portfolio: Alphawave Semi’s PCI-Express Solution

About Nubis Communications

Nubis innovates across photonics, electronics, packaging, and manufacturing to create optics with significantly better scalability, density, and power efficiency than existing solutions, breaking the I/O wall in data centers and enabling more advanced computing, AI, and machine learning. For more information visit https://www.nubis-inc.com.

XT-1600, HDI/O, and the Nubis Cloud Logo are trademarks of Nubis Communications.

About Alphawave Semi

Alphawave Semi is a global leader in high-speed connectivity and compute silicon for the world’s technology infrastructure. Faced with the exponential growth of data, Alphawave Semi’s technology services a critical need: enabling data to travel faster, more reliably and with higher performance at lower power. We are a vertically integrated semiconductor company, and our IP, custom silicon, and connectivity products are deployed by global tier-one customers in data centers, compute, networking, AI, 5G, autonomous vehicles, and storage. Founded in 2017 by an expert technical team with a proven track record in licensing semiconductor IP, our mission is to accelerate the critical data infrastructure at the heart of our digital world. To find out more about Alphawave Semi, visit: awavesemi.com.

Alphawave Semi and the Alphawave Semi logo are trademarks of Alphawave IP Group plc. All rights reserved.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130752202/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye